Horizon Wealth Management LLC Cuts Stock Position in iShares Biotechnology ETF $IBB

Posted by Francis Steltz on Jul 2nd, 2026

Horizon Wealth Management LLC decreased its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 96.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,734 shares of the financial services provider’s stock after selling 52,923 shares during the quarter. Horizon Wealth Management LLC’s holdings in iShares Biotechnology ETF were worth $293,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Citigroup Inc. increased its stake in shares of iShares Biotechnology ETF by 40.9% in the fourth quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after acquiring an additional 1,521,992 shares during the period. Morgan Stanley increased its stake in shares of iShares Biotechnology ETF by 2.5% during the fourth quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock worth $540,760,000 after purchasing an additional 76,978 shares in the last quarter. BNP Paribas Financial Markets increased its stake in iShares Biotechnology ETF by 11.4% during the 4th quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock worth $360,064,000 after buying an additional 218,066 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of iShares Biotechnology ETF by 286.2% during the fourth quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock worth $167,810,000 after buying an additional 736,881 shares in the last quarter. Finally, LPL Financial LLC increased its holdings in shares of iShares Biotechnology ETF by 145.9% in the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock valued at $167,555,000 after purchasing an additional 589,033 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of IBB stock opened at $190.12 on Thursday. The company’s 50-day moving average price is $172.32 and its 200-day moving average price is $171.49. iShares Biotechnology ETF has a twelve month low of $127.11 and a twelve month high of $191.15.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were issued a $0.0238 dividend. The ex-dividend date was Monday, June 15th. This represents a $0.10 dividend on an annualized basis and a yield of 0.1%.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.